Pharmaceuticals

Neurological Disorder Drugs Industry Anticipated to Expand at 5.6% CAGR During the Forecast Period

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Neurological Disorder Drugs Market By 2029?

The neurological disorder drugs market has experienced substantial expansion in recent years. It is projected to grow from $84.6 billion in 2024 to $89.24 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.5%. The notable growth observed historically can be attributed to increasing animal testing leading to promising findings, a rise in available therapeutic treatments, the growing incidence of neurological problems, various government initiatives, and an overall increase in healthcare expenditure.

The neurological disorder drugs market size is projected to experience significant growth in the coming years. It is forecast to expand to $110.99 billion by 2029, achieving a compound annual growth rate (CAGR) of 5.6%. This expansion during the forecast period can be attributed to the broadening range of therapeutic options and personalized therapies, an increasing emphasis on disease-modifying treatments, the wider adoption of digital biomarkers, and the rising prevalence of neurological diseases. Prominent trends expected in this period include advances in drug design, progress in neuroimaging, breakthroughs in genetic research, an increase in collaborations and licensing agreements, and the emergence of regenerative medicine.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Which Industry Drivers Are Expected To Accelerate The Neurological Disorder Drugs Market From 2025 To 2029?

The rising occurrence of neurological diseases is projected to propel the expansion of the neurological disorder drugs market. Neurological disorders describe conditions affecting the brain, spinal cord, and nerves, stemming from structural, biochemical, or electrical irregularities that lead to various symptoms. The growth in neurological diseases is attributed to the world’s aging population and increased exposure to environmental, metabolic, and lifestyle risk factors. Medications for neurological disorders are vital in managing these complex conditions, offering symptom alleviation, slowing disease progression, and improving long-term patient outcomes. For instance, in September 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, projected that the number of people living with dementia in Australia will more than double between 2023 and 2058, rising from approximately 411,100 in 2023 to 849,300 by 2058, with around 315,500 men and 533,800 women affected. Therefore, the increasing prevalence of neurological disease is driving the growth of the neurological disorder drugs market.

What Are The Emerging Segments Gaining Attention In The Neurological Disorder Drugs Market?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Trends Are Redefining The Neurological Disorder Drugs Market Dynamics?

Key players within the neurological disorder drugs market are concentrating their efforts on creating advanced Ocrelizumab drug therapies. The aim is to boost treatment effectiveness, achieve better patient results, and broaden the available therapeutic choices for those affected by multiple sclerosis. Ocrelizumab functions as a humanized monoclonal antibody, employed therapeutically for multiple sclerosis (MS), which is categorized as a neurological disorder. An example of this trend occurred in February 2024, when Roche Holding AG, a pharmaceutical firm headquartered in Switzerland, introduced Ocrevus (Ocrelizumab) in India. This marked the debut of a new disease-modifying therapy (DMT) specifically for multiple sclerosis treatment. Supported by over 10 years of clinical and real-world data, Ocrevus holds the distinction of being the initial and sole approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). As a monoclonal antibody, it specifically targets CD20-positive B cells, which are understood to contribute to the autoimmune assault on the central nervous system observed in multiple sclerosis (MS). Ocrevus is prescribed for the treatment of both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), thereby becoming the inaugural drug sanctioned for addressing both manifestations of the condition. Its administration is intravenous, generally occurring every six months, and clinical trials have demonstrated its effectiveness in diminishing disease activity and slowing the progression of disability.

Who Are The Top Performing Companies In The Neurological Disorder Drugs Market In Recent Years?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

What Regional Growth Trends Are Shaping The Neurological Disorder Drugs Market Outlook?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Neurological Disorder Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Browse Through More Reports Similar to the Global Neurological Disorder Drugs Market 2025, By The Business Research Company

Rare Neurological Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Neurological Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Hpv Associated Disorders Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795